FOR UK HEALTHCARE PROFESSIONALS ONLY
For UK Healthcare Professionals Only

Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

  1. Home
  2. Atopic dermatitis
  3. DUPIXENT
  4. Mode of Action DUPIXENT

DUPIXENT specifically targets a source of underlying inflammation in AD1

  • IL-4 and IL-13 are important in the development of Type 2 inflammation and its downstream effects1
  • DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1

Learn more about how
DUPIXENT works


Watch video

DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131

DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4

  • Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131–4
  • Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41
  • Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131

DUPIXENT is a targeted immunomodulator
unlike broad spectrum immunosuppressants1

UNDERLYING TYPE 2 INFLAMMATION

Overview of AD

Find out more about how AD has a continuous inflammation cycle.

Find out more

Request a representative call

Have questions about DUPIXENT?
Get answers from a representative.

Find out more

Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.

Find out more

AD, atopic dermatitis; γC, gamma C subunit; IL, interleukin; IL-4Rα; Interleukin 4 receptor alpha; IL-13Rα1, interleukin 13 receptor alpha 1; ILC, innate lymphoid cells; JAK, Janus kinase; Th, T-helper cells; TYK2, tyrosine kinase 2.

References

  1. DUPIXENT Summary of Product Characteristics. September 2021.
  2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.
  3. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
  4. D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
  5. McCormick M, et al. Cytokine. 2015;75(1):38–50.